MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription
Death receptor 4 (DR4) is a cell surface protein that is generally thought to mediate apoptosis upon binding to its ligand named TRAIL. However, its contribution to apoptosis resistance has also been reported. MET (or c-MET) gene amplification represents an important mechanism for acquired resistanc...
Main Authors: | Liang Deng, Karin A. Vallega, Shuo Zhang, Puyu Shi, Shi-Yong Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-08-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558621000476 |
Similar Items
-
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019-11-01) -
Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
by: Huang K, et al.
Published: (2018-09-01) -
Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
by: Ling Li, et al.
Published: (2020-09-01) -
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
by: Wang X, et al.
Published: (2016-09-01) -
Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
by: Tao Yu, et al.
Published: (2020-05-01)